1. Home
  2. EPOW vs NEUP Comparison

EPOW vs NEUP Comparison

Compare EPOW & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EPOW

Sunrise New Energy Co. Ltd

HOLD

Current Price

$0.64

Market Cap

27.5M

ML Signal

HOLD

NEUP

Neuphoria Therapeutics Inc.

HOLD

Current Price

$4.72

Market Cap

28.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
EPOW
NEUP
Founded
2014
1996
Country
China
United States
Employees
N/A
8
Industry
Business Services
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
27.5M
28.7M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
EPOW
NEUP
Price
$0.64
$4.72
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$21.00
AVG Volume (30 Days)
511.4K
43.7K
Earning Date
05-15-2026
05-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.57
$3.65
52 Week High
$1.86
$21.31

Technical Indicators

Market Signals
Indicator
EPOW
NEUP
Relative Strength Index (RSI) 40.29 39.31
Support Level $0.58 $3.91
Resistance Level $1.06 $5.06
Average True Range (ATR) 0.06 0.32
MACD -0.00 -0.05
Stochastic Oscillator 28.69 27.68

Price Performance

Historical Comparison
EPOW
NEUP

About EPOW Sunrise New Energy Co. Ltd

E Power Inc, through its subsidiaries, is engaged in the manufacturing and sale of graphite anode material for lithium-ion batteries. It operates a plant in Guizhou Province, China, powered by electricity from renewable sources, which contributes to the plant's low production costs and reduced environmental impact in the production of graphite anode materials. Additionally, the Group also operates a knowledge-sharing platform business. Its reportable operating segments are: Graphite anode business, which generates the maximum revenue, and Knowledge sharing and enterprise business. Substantially all of the Group's revenue is derived in the People's Republic of China (the PRC).

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: